Chat with us, powered by LiveChat

Loading...

Sepsis Diagnostic Market Report

RA00244

Sepsis Diagnostic Market, by Product (Instruments, Blood Culture Media, Assay Kits and Reagents, Software), by Technology (Microbiology, Molecular Diagnostics, Immunoassays, Flow Cytometry), by Testing Type (Laboratory Testing, PoC Testing), by Regional Analysis (North America, Europe, Asia-Pacific, LAMEA): Global Opportunity Analysis and Industry Forecast, 2020–2027

RA00244

Pages: NA

Jun 2020

COVID-19

pandemic has shown to have an enormous impact on most
industries.

Click Here to access our comprehensive analysis of the

Impact of covid-19 on Sepsis Diagnostic Market

Sepsis is a systematic illness caused by a microbial pathogen, which later causes the cloning of the human proinflammatory cytokines and their receptors, leading to inflammation.  It is caused when the chemicals released by the immune system against the microbes are released into the bloodstream in response to the infection throughout the body. In severe cases, it can even lead to death.  As per the WHO report in 2018 April, sepsis has affected more than 30 million people around the globe and 6 million deaths per year. The WHO revealed the data that almost 3 million new-borns and 1.2 children are suffering from sepsis disease every year.

Sepsis Diagnostic Market Analysis:

Sepsis is a dangerous condition caused because of infection, which can bring about organ damage, tissue necrosis and lead to death if left untreated. It is considered as a condition with three stages which begins with sepsis, prompting to serious sepsis, lastly septic shock. If sepsis reaches to the final stage of septic shock it leads to a drop in blood pressure drastically and ultimately leads to death. Moreover, sepsis happens because of the infectious condition in any of the body parts. The most common site of diseases is the lungs, pelvis, abdomen, and urinary tract.

Rising awareness of the early testing for detection of infection and fatality of sepsis are the major driving factors for the growth of the market in the forecasted period.

The drivers for the sepsis diagnostic market are currently, the diagnostic test for this disease can take up to 72 hours to obtain the results. So, there is a huge demand for the rapid diagnostic test, which would detect the fatal disease in a much earlier stage and could save many lives. The researchers at the University of Strathclyde have developed a relatively lesser cost diagnostic testing in 2019, which uses a microelectrode to analyze the blood of a patient and get the results in just 2 minutes and 30 seconds. The key players can capture this opportunity to strengthen their position in the market during the forecast period by developing and launching such tests. Some NGOs are creating awareness about the early detection of sepsis through initiatives cause awareness and demand for diagnostic testing solutions. An increase in technological advancements, and regulatory approvals are expected to drive the market was there in the estimated period.

Nonspecific physiological and clinical tests followed by advanced testing for confirmation are making it much costlier, which may inhibit the market in the forecasted period.

Currently, the test available for the diagnosis of sepsis is based on nonspecific physiological and clinical criteria, which are making it more difficult to differentiate sepsis form from a normal inflammation. A blood test is used in the identification of clotting and impaired oxygen availability. Tests like urine and respiratory regulations have to be followed after the blood test for further confirmation. If the source of infection is not found, then even X-Ray, CT scan, ultrasound MRI needs to be done, which are making diagnosis costlier. These aspects are predicted to hamper the market growth in the forecast period.

Sepsis Diagnostic Market, by Product:

The blood culture media segment is the largest revenue generator due to its comparatively low cost and is expected to grow in the forecast period.

The blood culture media segment is predicted to have the highest revenue and is expected to continue its dominance in the estimated period. The segment is predicted to grow due to the lesser cost involved and is most widely used by physicians. The Assay kits and reagents segment is predicted to have the highest growth rate in the forecast period. Increasing demand for the kits and reagents in core regions with the rising awareness against the disease is predicted to boost the market in the forecast period.

Sepsis Diagnostic Market, by Technology:

Microbiology segment to dominate its market share over the forecast period

The microbiology segment has the largest share in revenue generation and is expected to be dominant in the forecast period. Microbiology aids for quantitative detection and helps in identifying microorganisms by blood culture media tests, which is predicted to boost the segment in the forecast period. The diagnosis segment is also expected to show tremendous growth in the estimated period. The diagnosis segment is predicted to have the highest market share in the forecast period. Increased use of molecular diagnostic testing due to its advantages like accuracy, less turnaround time, and much higher sensitivity is predicted to drive the market in the forecast period. 

Sepsis Diagnostic Market, by Testing Type:

The laboratory testing segment will continue to show significant growth in the estimated period.

The laboratory testing segment held a significant market share in the year 2018. An increasing number of blood culture tests conducted in the laboratories is predicted to drive the market in the forecast period. This aspect coupled with advanced instrument availability is predicted to be the major driving factor for the market.

Sepsis Diagnostic Market, by Region:

North American regional segment shows dominance in the market

North American region has a significant position in terms of revenue and market share and is expected to grow and continue the dominance in the forecast period due to an increase in healthcare expenditure and reimbursement for the diagnostic tests. There is a well-established healthcare infrastructure with rapid transformation into technologically advanced diagnostic products in this segment, which will drive the growth of the market in this region. 

Asia-Pacific region market is also expected to have a significant growth in the estimated period. The players in this segment are adopting organic growth strategy through product development and launches for getting a better market share, and the increase of disease in the Asia-Pacific market is expected to drive the growth for this region.

Key players in the Sepsis Diagnostics market:

The market players in the sepsis diagnostic market are Becton, Dickinson and Company, bioMérieux SA, Sysmex Corporation, F. Hoffmann-La Roche AG, Beckman Coulter, Inc., Thermo Fisher Scientific, Inc., Cepheid Inc., Bruker Corporation, and Nanosphere, Inc. These players are adopting new technologies and strategies, and they are undergoing mergers and partnerships to penetrate more regions globally and offer their solutions in a much wider space.

Aspect

Particulars

  Historical Market Estimations

  2019-2020

  Base Year for Market Estimation

  2020

  Forecast timeline for Market Projection

  2020-2027

  Geographical Scope

  North America, Europe, Asia-Pacific, LAMEA

  Segmentation by Technology

  • Microbiology
  • Molecular Diagnostics
  • Immunoassays
  • Flow Cytometry

  Segmentation by Testing type

  • Laboratory Testing
  • PoC Testing

  Segmentation by Product

  • Instruments
  • Blood Culture Media
  • Assay Kits
  • Reagents, Software

  Key Countries Covered

U.S., Canada, U.K., Germany, Spain, France, Italy, Russia, Japan, India, China, South Korea, Singapore, Australia, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, UAE

  Key Companies Profiled

  • Becton, Dickinson and Company
  • BioMérieux SA
  • Sysmex Corporation
  • F. Hoffmann-La Roche AG
  • Beckman Coulter, Inc.
  • Thermo Fisher Scientific, Inc.
  • Cepheid Inc.
  • Bruker Corporation
  • Nanosphere, Inc.

 


Frequently Asked Questions
 

A. Becton, Dickinson and Company is the leading company in the Sepsis diagnostic market.

A. The North America region possesses great investment opportunities for investors to witness the most promising growth in the future.

A. Mergers and strategic partnerships are the strategies adopted by players globally to enter new market regions.

A. The microbiology technology segment has higher growth opportunities due to its relatively lesser cost.

Research Methodology

Purchase Options

Inquire To Buy

Personalize this research

  • Triangulate with your own data
  • Request your format and definition
  • Get a deeper dive on a specific application, geography, customer or competitor
10% Off on Customization
Contact Us

Customers Also Viewed